Idexx Laboratories, Inc. (IDXX) Tops Q2 EPS by 11c; Boosts FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $569.77 +0.04%
Revenue Growth %: +8.2%
Financial Fact:
Provision for income taxes: 25.07M
Today's EPS Names:
GFL, ARIS, QCOM, More
Revenue Growth %: +8.2%
Financial Fact:
Provision for income taxes: 25.07M
Today's EPS Names:
GFL, ARIS, QCOM, More
Join SI Premium – FREE
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q2 EPS of $0.83, $0.11 better than the analyst estimate of $0.72. Revenue for the quarter came in at $317.9 million versus the consensus estimate of $308.58 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plexus Corp (PLXS) Tops Q3 EPS by 19c ; Offers Guidance
- IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
- IDEXX Laboratories (IDXX) PT Lowered to $620 at UBS
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
